Last reviewed · How we verify
pentaerythritol
pentaerythritol is a drug. It is currently in unknown development.
At a glance
| Generic name | pentaerythritol |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Approved indications
Common side effects
Key clinical trials
- Randomized Controlled and Single Blind Clinical Trial in Women With Breast Cancer and Axillary Lymphadenectomy, to Evaluate the Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Dra (Phase 4)
- Phase I Dose Escalation Study of the Use of ACU-D1, a Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pentaerythritol CI brief — competitive landscape report
- pentaerythritol updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about pentaerythritol
What is pentaerythritol?
pentaerythritol is a pharmaceutical drug.
What development phase is pentaerythritol in?
pentaerythritol is in unknown.
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing